01
Cash & equivalents decreased 31.9%
Cash & equivalents changed -31.9% from the comparable as-filed period.
$6.5M→$4.4MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTDermata Therapeutics, Inc.'s latest supported as-filed period reports net income of -$3.0M, 74.4% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -31.9% from the comparable as-filed period.
Net income changed -74.4% from the comparable as-filed period.
Operating income changed -70.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
DRMA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-039048SEC ↗4Aug 18, 2026Period Aug 16, 20260001493152-26-039046SEC ↗8-KAug 17, 2026Period Aug 16, 20260001493152-26-038647SEC ↗10-QAug 11, 2026Period Jun 30, 20260001493152-26-037127SEC ↗8-KAug 11, 2026Period Aug 11, 20260001493152-26-037124SEC ↗8-KAug 5, 2026Period Aug 5, 20260001493152-26-036109SEC ↗4Jun 16, 2026Period Jun 16, 20260001493152-26-028884SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 16, 2026Filed Aug 18, 2026 | PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO | Grant Or AwardIndirect | 170,068 | — | — | Form 4 ↗ |
| Aug 16, 2026Filed Aug 18, 2026 | PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO | Grant Or AwardIndirect | 1,360,544 | — | — | Form 4 ↗ |
| Aug 16, 2026Filed Aug 18, 2026 | PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO | Grant Or AwardIndirect | 1,360,544 | — | — | Form 4 ↗ |
| Aug 16, 2026Filed Aug 18, 2026 | PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO | Grant Or AwardIndirect | 170,068 | — | — | Form 4 ↗ |
| Aug 16, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -65.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +6.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-025441| PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO |
| Grant Or AwardIndirect |
| 170,068 |
| — |
| — |
| Form 4 ↗ |
| Aug 16, 2026Filed Aug 18, 2026 | PROEHL GERALD TPRESIDENT, CHAIRMAN, CEO | Grant Or AwardIndirect | 1,360,544 | — | — | Form 4 ↗ |